Arrowhead Research | ARWR - Ebit



Arrowhead Research reported $-165550000 in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD 4.89M 13.19M Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
Incyte USD 310.82M 27.18M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
Ligand Pharmaceuticals USD 43.56M 92.88M Jun/2025
Merck USD 6.36B 149M Jun/2025
Moderna USD -817000000 146M Jun/2025
Novartis USD -9190000000 13.87B Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
TG Therapeutics USD 34.84M 22.62M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 420.8M Jun/2025
Xencor USD -22832000 16.77M Jun/2025